Drug Profile
Tamoxifen methiodide
Alternative Names: PRS 311.003; Tamoxifen methyl iodide; TMILatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Pharmos Corporation; Weizmann Institute of Science
- Class Antineoplastics; Phenyl ethers; Small molecules; Stilbenes; Trimethyl ammonium compounds
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Nov 2002 No development reported - Preclinical for Cancer in Israel (unspecified route)
- 26 Nov 2002 No development reported - Preclinical for Cancer in USA (unspecified route)
- 25 Feb 2000 Pharmos has been granted a new patent for permanently charged steroid hormone derivatives in the USA